Details for Patent: RE41884
✉ Email this page to a colleague
Summary for Patent: RE41884
Title: | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
Abstract: | Disclosed are methods of intravenous administration of nanoparticulate drug formulations to a mammal to avoid adverse hemodynamic effects: by reducing the rate and concentration of the nanoparticles in the formulations; or by pre-treating the subject with histamine; or by pretreating the subject with a desensitizing amount of the nanoparticulate drug formulations. |
Inventor(s): | de Garavilla; Lawrence (Downington, PA), Liversidge; Elaine (West Chester, PA), Liversidge; Gary G. (West Chester, PA) |
Assignee: | Elan Pharma International Limited (Co. Clare, IR) |
Application Number: | 12/027,100 |
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent RE41884
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent RE41884
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 7117196 | ⤷ Try a Trial | |||
Canada | 2232879 | ⤷ Try a Trial | |||
European Patent Office | 0859604 | ⤷ Try a Trial | |||
European Patent Office | 2275094 | ⤷ Try a Trial | |||
Japan | 2001518059 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |